About
Corporate Overview
Management Team
Board of Directors
Partnerships
Products
Pipeline
Our Medicine
Tivozanib
Ficlatuzumab
AV
-203
AV
-380
AV
-353
Expanded Access Policy
Publications & Presentations
Media
Press Releases
Media Toolkit
Investors
Overview
Corporate Governance
Stock Information
Research Coverage
Interactive Analyst Center
SEC Filings
Annual Reports
Press Releases
Scientific Publications & Presentations
Calendar of Events
FAQs
Information Request
Careers
Life at AVEO
Job Openings
Contact
Scarlett Spring
About
Corporate Overview
Management Team
Board of Directors
Partnerships
Products
Pipeline
Our Medicine
Tivozanib
Ficlatuzumab
AV
-203
AV
-380
AV
-353
Expanded Access Policy
Publications & Presentations
Media
Press Releases
Media Toolkit
Investors
Overview
Corporate Governance
Stock Information
Research Coverage
Interactive Analyst Center
SEC Filings
Annual Reports
Press Releases
Scientific Publications & Presentations
Calendar of Events
FAQs
Information Request
Careers
Life at AVEO
Job Openings
Contact
Still Not Management.php
Click
Here
To View Our ASCO Poster:
TIVO-3: Final OS Analysis Of A Phase III, Randomized, Controlled, Multicenter, Open-Label Study To Compare Tivozanib To Sorafenib In Subjects With Metastatic Renal Cell Carcinoma (RCC)
###
About
Corporate Overview
Management Team
Board of Directors
Partnerships
Products
Pipeline
Our Medicine
Tivozanib
Ficlatuzumab
AV
-203
AV
-380
AV
-353
Expanded Access Policy
Publications & Presentations
Media
Press Releases
Media Toolkit
Investors
Overview
Corporate Governance
Stock Information
Research Coverage
Interactive Analyst Center
SEC Filings
Annual Reports
Press Releases
Scientific Publications & Presentations
Calendar of Events
FAQs
Information Request
Careers
Life at AVEO
Job Openings
Contact
